Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big potential implications for novel oral anticoagulants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Anticoagulant antidotes start yielding Phase III promise. Nat Rev Drug Discov 14, 5–6 (2015). https://doi.org/10.1038/nrd4527
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4527
This article is cited by
-
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy
Journal of Thrombosis and Thrombolysis (2018)
-
FDA approves anticoagulant antidote
Nature Reviews Drug Discovery (2015)